YU75201A - Novi polimorfni oblik 5-/4-/2-(n-metil-n-(2-piridil)amino/ etoksi/benzil/tiazolidin-2,4-dion, soli maleinske kiseline - Google Patents

Novi polimorfni oblik 5-/4-/2-(n-metil-n-(2-piridil)amino/ etoksi/benzil/tiazolidin-2,4-dion, soli maleinske kiseline

Info

Publication number
YU75201A
YU75201A YU75201A YUP75201A YU75201A YU 75201 A YU75201 A YU 75201A YU 75201 A YU75201 A YU 75201A YU P75201 A YUP75201 A YU P75201A YU 75201 A YU75201 A YU 75201A
Authority
YU
Yugoslavia
Prior art keywords
ethoxy
benzyl
amino
methyl
maleic acid
Prior art date
Application number
YU75201A
Other languages
English (en)
Inventor
Paul David James Blacker
Robert Gordon Giles
Michael John Sasse
Original Assignee
Smithkline Beechaam P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315460&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU75201(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9909472.4A external-priority patent/GB9909472D0/en
Priority claimed from GBGB9912197.2A external-priority patent/GB9912197D0/en
Application filed by Smithkline Beechaam P.L.C. filed Critical Smithkline Beechaam P.L.C.
Publication of YU75201A publication Critical patent/YU75201A/sh
Publication of RS50114B publication Critical patent/RS50114B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Polimorfni oblik soli maleinske kiseline i 5-[4-[2-(N-metil-N-(2-piridil)amino)etoksi]benzil]tizolidin-2,4-diona (Polimorf), koga karakterišu: (i) infracrveni spektar koji sadrži pikove 1360, 1326, 1241, 714 i 669 cm-1; i/ili (ii) Raman-ov spektar koji sadrži pikove 1581, 768, 670, 271 i 226 cm-1; i/ili (ili) spektar nuklearne magnetne rezonance čvrste faze, koji sadrži pikove i hemijska pomeranja koja su u suštini data u Tabeli; i/ili (iv) spektar difrakcije X-zraka praha (XRPD) koji sadrži pikove koji su u suštini dati u Tabeli II; postupak za dobijanje tog jedinjenja, farmaceutski preparat koji sadrži to jedinjenje i upotrebu tog jedinjenja u medicini.
YUP-752/01A 1999-04-23 2000-04-19 Novi polimorfni oblik 5-/4-/2-(n-metil- n-(2-piridil)amino/ etoksi/benzil/ tiazolidin-2,4-dion, soli maleinske kiseline RS50114B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9909472.4A GB9909472D0 (en) 1999-04-23 1999-04-23 Novel compounds
GBGB9912197.2A GB9912197D0 (en) 1999-05-25 1999-05-25 Novel pharmaceutical

Publications (2)

Publication Number Publication Date
YU75201A true YU75201A (sh) 2004-09-03
RS50114B RS50114B (sr) 2009-03-25

Family

ID=26315460

Country Status (40)

Country Link
US (2) US6815457B1 (sh)
EP (3) EP1173434B1 (sh)
JP (1) JP2002543075A (sh)
KR (1) KR100744359B1 (sh)
CN (1) CN1208335C (sh)
AP (1) AP1495A (sh)
AR (2) AR023568A1 (sh)
AT (2) ATE382046T1 (sh)
AU (1) AU765498B2 (sh)
BG (1) BG65427B1 (sh)
BR (1) BR0009934A (sh)
CA (1) CA2370258A1 (sh)
CO (1) CO5170424A1 (sh)
CY (1) CY1107238T1 (sh)
CZ (1) CZ20013799A3 (sh)
DE (2) DE60037602T2 (sh)
DK (2) DK1284268T3 (sh)
DZ (1) DZ3155A1 (sh)
EA (1) EA004534B1 (sh)
ES (2) ES2298327T3 (sh)
HK (2) HK1055293A1 (sh)
HR (1) HRP20010773B1 (sh)
HU (1) HUP0200929A3 (sh)
IL (1) IL146110A0 (sh)
MA (1) MA26785A1 (sh)
MX (1) MXPA01010820A (sh)
MY (1) MY128007A (sh)
NO (1) NO320589B1 (sh)
NZ (1) NZ515163A (sh)
OA (1) OA11871A (sh)
PE (1) PE20010040A1 (sh)
PL (1) PL351686A1 (sh)
PT (2) PT1173434E (sh)
RS (1) RS50114B (sh)
SK (1) SK286423B6 (sh)
TR (1) TR200103061T2 (sh)
TW (1) TW591027B (sh)
UA (1) UA67843C2 (sh)
UY (1) UY26120A1 (sh)
WO (1) WO2000064892A2 (sh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) * 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
US6806280B1 (en) 1999-04-23 2004-10-19 Smithkline Beecham P.L.C. Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt
US20040248945A1 (en) 1999-04-23 2004-12-09 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
GB0006133D0 (en) 2000-03-14 2000-05-03 Smithkline Beecham Plc Novel pharmaceutical
US7241895B2 (en) * 2000-09-26 2007-07-10 Dr. Reddy's Laboratories Limited Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
HUP0301161A3 (en) * 2000-09-26 2005-04-28 Reddy S Res Foundation Hyderab Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation
AU2002352391A1 (en) * 2001-12-13 2003-06-23 Smithkline Beecham Plc A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
WO2003053962A1 (en) * 2001-12-20 2003-07-03 Smithkline Beecham Plc 5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
GB0130511D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0307259D0 (en) * 2003-03-28 2003-05-07 Glaxo Group Ltd Process
EP1468997A3 (en) * 2003-04-18 2004-11-03 CHEMI S.p.A. Polymorphous forms of rosiglitazone maleate
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
EP1709038A2 (en) * 2004-01-28 2006-10-11 Usv Limited A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
US7435741B2 (en) 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
DE3856378T2 (de) 1987-09-04 2000-05-11 Beecham Group Plc Substituierte Thiazolidindionderivate
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5457109A (en) * 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH09512249A (ja) 1994-02-10 1997-12-09 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 腎臓疾患を治療するためのインスリンセンシタイザーの使用
US20010044458A1 (en) * 1994-02-10 2001-11-22 Smithkline Beechamp P.L.C. Use of insulin sensitisers for treating renal diseases
DE4404198A1 (de) 1994-02-10 1995-08-17 Henkel Kgaa 2-Fluor-6-nitroaniline
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
GB9711683D0 (en) 1997-06-05 1997-08-06 Smithkline Beecham Plc Composition
ATE353654T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und sulphonylurea
US20020028768A1 (en) * 1997-06-18 2002-03-07 Smithkline Beecham P.L.C. Treatment of diabetes with rosiglitazone and insulin
PT996444E (pt) 1997-06-18 2007-06-08 Smithkline Beecham Plc Tratamento de diabetes com tiazolidinodiona e metformina
GB9712866D0 (en) 1997-06-18 1997-08-20 Smithkline Beecham Plc Novel method of treatment
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
PL337577A1 (en) 1997-06-18 2000-08-28 Smithkline Beecham Plc Treatment of diabetes with thiazolydinone and alpha - glucosidaze inhibitor
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020045649A1 (en) * 1997-07-18 2002-04-18 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione and sulphonylurea
US20020016287A1 (en) * 1997-07-18 2002-02-07 Smithkline Beecham P.L.C. Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
GB9726563D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9726566D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
KR100744359B1 (ko) 1999-04-23 2007-07-30 스미스클라인비이참피이엘시이 티아졸리딘디온 유도체 및 항당뇨병제로서 그의 용도
US6806280B1 (en) 1999-04-23 2004-10-19 Smithkline Beecham P.L.C. Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt
NZ515167A (en) 1999-04-23 2004-02-27 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
HUP0301161A3 (en) 2000-09-26 2005-04-28 Reddy S Res Foundation Hyderab Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl]thiazolidine-2,4-dione maleate and process for their preparation

Also Published As

Publication number Publication date
DE60004658D1 (de) 2003-09-25
HK1055293A1 (en) 2004-01-02
JP2002543075A (ja) 2002-12-17
HRP20010773B1 (en) 2005-06-30
HK1045154B (zh) 2004-06-25
DE60004658T2 (de) 2004-06-24
UY26120A1 (es) 2000-12-29
NO320589B1 (no) 2005-12-27
MA26785A1 (fr) 2004-12-20
ATE382046T1 (de) 2008-01-15
DK1284268T3 (da) 2008-04-28
HK1045154A1 (en) 2002-11-15
CY1107238T1 (el) 2012-11-21
CZ20013799A3 (cs) 2002-04-17
TW591027B (en) 2004-06-11
EP1284268B1 (en) 2007-12-26
MY128007A (en) 2007-01-31
ES2204557T3 (es) 2004-05-01
EP1903043A1 (en) 2008-03-26
WO2000064892A3 (en) 2001-01-25
RS50114B (sr) 2009-03-25
NO20015149L (no) 2001-12-17
DZ3155A1 (fr) 2000-11-02
US20040092555A1 (en) 2004-05-13
AR023568A1 (es) 2002-09-04
NO20015149D0 (no) 2001-10-22
ES2298327T3 (es) 2008-05-16
CN1208335C (zh) 2005-06-29
EP1173434B1 (en) 2003-08-20
IL146110A0 (en) 2002-07-25
WO2000064892A2 (en) 2000-11-02
HRP20010773A2 (en) 2002-10-31
EP1284268A1 (en) 2003-02-19
NZ515163A (en) 2004-02-27
PT1173434E (pt) 2003-12-31
PT1284268E (pt) 2008-03-10
HUP0200929A3 (en) 2004-03-29
SK14912001A3 (sk) 2002-02-05
DE60037602T2 (de) 2009-01-08
PL351686A1 (en) 2003-06-02
OA11871A (en) 2006-03-27
BR0009934A (pt) 2002-06-04
DK1173434T3 (da) 2003-12-08
KR100744359B1 (ko) 2007-07-30
CO5170424A1 (es) 2002-06-27
EA004534B1 (ru) 2004-06-24
AU4130600A (en) 2000-11-10
TR200103061T2 (tr) 2002-05-21
DE60037602D1 (de) 2008-02-07
UA67843C2 (uk) 2004-07-15
US6815457B1 (en) 2004-11-09
CN1355801A (zh) 2002-06-26
BG106119A (en) 2002-05-31
EP1173434A2 (en) 2002-01-23
ATE247653T1 (de) 2003-09-15
MXPA01010820A (es) 2002-06-04
AP1495A (en) 2005-11-30
CA2370258A1 (en) 2000-11-02
AU765498B2 (en) 2003-09-18
KR20020028873A (ko) 2002-04-17
SK286423B6 (sk) 2008-09-05
EA200101119A1 (ru) 2002-04-25
HUP0200929A2 (en) 2002-08-28
PE20010040A1 (es) 2001-03-10
BG65427B1 (bg) 2008-07-31
AR023564A1 (es) 2002-09-04

Similar Documents

Publication Publication Date Title
YU75201A (sh) Novi polimorfni oblik 5-/4-/2-(n-metil-n-(2-piridil)amino/ etoksi/benzil/tiazolidin-2,4-dion, soli maleinske kiseline
YU75301A (sh) Polimorfni oblik soli maleinske kiseline i 5-(4-(2-(n-metil- n-(2-piridil)amino)etoksi)benzil)-tiazolidin-2,4-diona
UA66821C2 (uk) Гідрат солі малеїнової кислоти 5-[4-[2-(n-метил-n-(2-піридил)аміно) етокси]бензил]тіазолідин-2,4-діону, спосіб одержання вказаного гідрату та фармацевтична композиція на його основі
YU75401A (sh) Polimorfni oblik soli maleinske kiseline 5-/4-/2-(n-metil- -(2-piridil)amino)etoksi/-benzil/tiazolidin-2,4-dion
HUP0300158A2 (en) Hydrochloride salts of-5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, method for their production and pharmaceutical compositions containing them
WO2002016355A3 (en) Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
MY135612A (en) Novel pharmaceutical
KR20060006850A (ko) 아릴-헤테로방향족 생성물, 이를 함유하는 조성물 및 이의용도
AP1441A (en) Hydrate of 5- [4-{2-(N-methlyl-N-(2-pyridil) amino) ethoxy} benzyl] thiazolidine-2,4-dione maleic acid salt.
NZ337608A (en) Partial reduction of doubles bonds of five membered ring does not occur when using Al as reducing agent so 5-{4-[2-(5-methyl-2-phenyloxazol-4-yl)-ethoxy]-naphth-1-ylmethyl}-thiazolidine-2,4-dione reduced to 5-{4-[2-(5-methyl-2-phenyloxazo-4-yl)-ethoxy]-naphth-1-ylmethylidene}-thiazolidine-2,4-dione
YU81601A (sh) Nova so 5-/4-/2-(n-metil-n-(2-piridil)amino)etoksi/ tiazolidin-2,4-dion hidrohlorid monohidrat
JP5927190B2 (ja) チアゾリジンジオン化合物のための新規合成
WO2004067495A1 (fr) Composes d'alanine, leur procede de preparation et leur utilisation
TH54464A (th) สารทางเภสัชกรรมชนิดใหม่
ECSP982781A (es) Hidrato de la sal de maleico de 5-[4- (-n -metil-n- (2-piridil) amino) etoxi) bensil) tiazolidina - 2,4 diona
ECSP982779A (es) Un hidrato de la sal de acido maleico, proceso para la preparacion, composicion farmaceutica y su uso en medicina